Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) fell 295.93% to $7.87 in Q4 2025 from the same period last year, while for Dec 2025 it was $41.57, marking a year-over-year increase of 845.29%. This contributed to the annual value of $41.48 for FY2025, which is 818.99% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at $7.87 for Q4 2025, which was down 295.93% from $13.62 recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $27.97 in Q2 2021 and a low of $6.27 during Q1 2024
Over the past 5 years, Regeneron Pharmaceuticals' median EPS (Weighted Average and Diluted) value was $10.15 (recorded in 2021), while the average stood at $11.25.
Per our database at Business Quant, Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) surged by 26754.27% in 2021 and then plummeted by 7329.28% in 2022.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $19.68 in 2021, then plummeted by 46.7% to $10.49 in 2022, then fell by 2.76% to $10.2 in 2023, then decreased by 20.49% to $8.11 in 2024, then dropped by 2.96% to $7.87 in 2025.
Its last three reported values are $7.87 in Q4 2025, $13.62 for Q3 2025, and $12.81 during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value